Evonik Aktie
WKN DE: EVNK01 / ISIN: DE000EVNK013
15.07.2024 12:18:32
|
EQS-Adhoc: Evonik Industries AG: Preliminary figures for the second quarter of 2024 and adjustment of the outlook for the financial year 2024
EQS-Ad-hoc: Evonik Industries AG / Key word(s): Half Year Results/Change in Forecast Evonik Industries AG is already today publishing the following preliminary figures for the second quarter of 2024 and adjusting its outlook for the financial year 2024.
Based on preliminary, non-audited figures, Evonik expects an adjusted EBITDA* of €578 million in the second quarter of 2024 (Q2 2023: €450 million). The current market expectation is €531 million (Vara Research analyst consensus as of May 29, 2024). As there was still no broad-based macroeconomic recovery, company-specific factors in particular led to this positive development: In addition to continued strict cost discipline, good volume development in Specialty Additives, as well as a price recovery in Animal Nutrition and lower production costs were drivers of the sequential increase. Based on this development, Evonik is raising its outlook for adjusted EBITDA* as follows: The company now expects adjusted EBITDA* for the financial year 2024 to be between €1.9 billion and €2.2 billion (previously: €1.7 - €2.0 billion). Following a slight decline in the first quarter, sales in the second quarter were, based on preliminary figures, at just above €3.9 billion and thus around the level of the previous year (Q2 2023: €3.9 billion). Evonik Industries AG will publish final figures for the second quarter of 2024 on August 1, 2024, as planned. *Notes on key performance indicators (KPIs) can be found in the Financial Report of Evonik Industries AG starting on page 240. The Financial Report 2023 is available at: https://files.evonik.com/shared-files/evonik-financial-report-2023-9492.pdf Contact/person making the notification: Tim Lange Head of Investor Relations +49 201 177-3150 tim.lange@evonik.com End of Inside Information
15-Jul-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | Evonik Industries AG |
Rellinghauser Straße 1-11 | |
45128 Essen | |
Germany | |
Phone: | +49 (0) 201 177-01 |
Fax: | +49 (0) 201 177-3475 |
E-mail: | investor-relations@evonik.com |
Internet: | www.evonik.com |
ISIN: | DE000EVNK013 |
WKN: | EVNK01 |
Indices: | MDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Luxembourg Stock Exchange |
EQS News ID: | 1946351 |
End of Announcement | EQS News Service |
|
1946351 15-Jul-2024 CET/CEST

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Evonik AGmehr Nachrichten
15:59 |
Pluszeichen in Frankfurt: MDAX präsentiert sich fester (finanzen.at) | |
12:27 |
Gute Stimmung in Frankfurt: MDAX mit Zuschlägen (finanzen.at) | |
04.06.25 |
EQS-DD: Evonik Industries AG: Christian Kullmann, Kauf (EQS Group) | |
04.06.25 |
EQS-DD: Evonik Industries AG: Christian Kullmann, buy (EQS Group) | |
04.06.25 |
MDAX-Titel Evonik-Aktie: So viel Verlust wäre bei einem Investment in Evonik von vor 5 Jahren angefallen (finanzen.at) | |
03.06.25 |
EQS-DD: Evonik Industries AG: Dr. Claudine Mollenkopf, buy (EQS Group) | |
03.06.25 |
EQS-DD: Evonik Industries AG: Dr. Claudine Mollenkopf, Kauf (EQS Group) | |
29.05.25 |
Pluszeichen in Frankfurt: MDAX beendet die Sitzung im Plus (finanzen.at) |
Analysen zu Evonik AGmehr Analysen
05.06.25 | Evonik Neutral | UBS AG | |
03.06.25 | Evonik Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
29.05.25 | Evonik Neutral | Goldman Sachs Group Inc. | |
27.05.25 | Evonik Buy | Deutsche Bank AG | |
26.05.25 | Evonik Neutral | UBS AG |
Aktien in diesem Artikel
Evonik AG | 19,06 | -1,45% |
|
Letzte Top-Ranking Nachrichten
08.06.25 | |
08.06.25 | |
07.06.25 | |
07.06.25 | |
06.06.25 |